An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

A 58-year-old woman in the UK has become the first person in the world to receive an experimental cell therapy for ovarian cancer.

Tracy Tomlinson, who has been living with advanced ovarian cancer for more than five years, received the first dose of ZI-MA4-1 at The Christie NHS Foundation Trust as part of the ZIMA-101 clinical trial. The study is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development.

"While this is an early-stage study primarily focused on safety, it represents an exciting step forward in efforts to develop new treatment options for people like Tracy with advanced solid tumors. We hope the knowledge gained will help shape future cancer treatments and ultimately improve outcomes for patients," said Professor Fiona Thistlethwaite, consultant medical oncologist at The Christie.

Tracy's Journey With Ovarian Cancer

Tracy, from Chadderton in Greater Manchester, was diagnosed with Stage 3C ovarian cancer shortly before Christmas 2020.

She first suspected something was wrong when what she thought was a urinary tract infection did not improve despite antibiotics prescribed by her GP. After blood tests, scans and further investigations, she was diagnosed with ovarian cancer just two days before her birthday.

Over the next several years, Tracy underwent surgery, multiple rounds of chemotherapy and maintenance therapy. By the summer of 2021, scans showed no evidence of disease, but the cancer returned a year later. She underwent further surgery and treatment, followed by additional recurrences.

Since 2023, Tracy has been living with ongoing cancer while receiving additional lines of treatment.

"The cancer is relentless," she said. "For me, it's never seemed to leave me alone."

Treatment has also caused fatigue, nausea and nerve damage in her hands and feet, eventually forcing her to stop working as a credit controller.

As her treatment options became more limited, Tracy began exploring clinical trials. Last year, she was referred to The Christie's early-phase clinical trials team and was eventually found eligible for the ZIMA-101 study.

After extensive screening, including scans, biopsies and blood tests, she became the first patient in the world to receive ZI-MA4-1.

"I decided almost straight away that I was going to go for it," she said. "Then afterwards you think, 'Am I doing the right thing?' because it is a little bit scary being the first person."

Following her first dose, Tracy remained in hospital for planned monitoring before being discharged on July 23.

"There are no guarantees with any trial," she said. "It could have a fantastic outcome, it could have no outcome, or somewhere in between. But if there is a possibility that it could work, I've got to go for it."

She added, "Cancer is no longer a death sentence. Five years ago, I thought I was going to die, but I'm still here."

What Is ZI-MA4-1 Cell Therapy?

Developed by Zelluna, ZI-MA4-1 combines two immune-based approaches to target cancer. The therapy uses natural killer (NK) cells, which can detect and destroy abnormal cells, together with engineered T-cell receptors (TCRs) that enable them to recognize tumors expressing the protein MAGE-A4.

MAGE-A4 is found in several solid tumors, including ovarian cancer, making it a promising target for precision cancer therapies.

Unlike personalized cell therapies that require a patient's own cells to be collected and manufactured individually, ZI-MA4-1 uses donor-derived immune cells and is designed as an "off-the-shelf" treatment.

Researchers hope this approach could make advanced cell therapies available to more patients in less time.

Reducing sugar intake during pregnancy and the first two years of a child’s life could have life-changing benefits for brain health, particularly in lowering the risk of Alzheimer’s disease.

According to a new study, limiting sugar intake could reduce the risk Alzheimer’s by more than 45% in the future.

The research, published in npj Aging, found that people exposed to lower sugar intake during the first 1,000 days of life, from conception until age two, had a 46% lower risk of Alzheimer’s disease, a 27% lower risk of dementia, an 11% lower risk of depression, and a 20% lower risk of anxiety in later life.

Researchers analysed health and brain imaging data from more than 60,000 participants in the UK Biobank.

They used Britain’s World War II sugar rationing period as a natural experiment, comparing people born when sugar availability was restricted with those born after rationing ended.

Why The First 1,000 Days Matter?

Scientists say that early life is a critical phase for the brain, metabolism, and immune system. Nutrition during this period can shape long-term health, influencing disease risk of neurodegenerative disease decades later.

“Our findings suggest that limiting sugar intake during the first 1,000 days of life may have long-lasting benefits for brain health,” the researchers noted, adding that the effects appear to persist well into older adulthood.

Dr. Bing Zhang, a geriatric medicine researcher involved in the study, said the results support the idea that nutrition in early life can shape lifelong brain health through metabolic programming during critical stages of development.

The study also found key structural differences in the brain. MRI scans showed that participants who had lower sugar exposure early in life had brains that appeared approximately 0.4 years younger biologically.

Their brains showed greater grey matter volume and fewer signs of white matter damage that is often linked to healthier cognitive ageing.

Also read: Can Your Child’s Diet Shape Future Diabetes Risk? Study Links Ultra-Processed Foods To Early Insulin Responses

Does Sugar Cause Dementia?

The researchers found an association, not proof that sugar directly causes Alzheimer’s or dementia. Since the study is observational, other factors like overall diet, access to healthcare facilities and services, and lifestyle may also have contributed to the findings.

Dr. Sara Rodrigues of Alzheimer’s Research UK, who was not involved in the research, cautioned that while the results are compelling, they do not establish cause and effect. However, they add to the growing evidence that healthy eating throughout life plays an important role in maintaining brain health.

Ultra-Processed Foods Linked To Early Insulin Response

This comes after a recent study suggested that children who who consume higher amounts of ultra-processed foods may already be showing subtle changes in the way their bodies regulate insulin, potentially increasing the risk for type 2 diabetes in the future.

According to a new study published in the journal Nutrients, children who have higher amounts of in ultra-processed foods (UPFs) had reduced insulin sensitivity and higher insulin secretion, even though they did not have diabetes.

Researchers from Texas A&M University–San Antonio, University of Texas Health San Antonio, University of Texas Rio Grande Valley, and Wake Forest University School of Medicine discovered that the metabolic changes linked to diabetes may begin much earlier in life than previously thought.

The Democratic Republic of the Congo’s (DRC) Ebola outbreak has become the second-largest Ebola epidemic ever recorded, overtaking the country’s devastating 2018-2020 outbreak.

The current epidemic has also underscored the growing global concern over the rapid spread of the deadly disease.

Second-Largest Ebola Outbreak In DR Congo

According to the latest official figures released by the DRC health authorities and the European Centre for Disease Prevention and Control (ECDC), the country has reported 3,442 confirmed Ebola cases and 1,521 deaths as of July 29, 2026.

However, more recent updates indicate the outbreak has continued to worsen rapidly, with 3,532 confirmed cases and 1,556 deaths reported by July 31, 2026.

The only Ebola outbreak larger than the current epidemic remains the 2014-2016 West Africa outbreak, which infected more than 28,000 people and resulted in the deaths of over 11,300 lives.

Also read: Milestone In Kala-Azar Treatment: WHO Updates Treatment Guidelines, Recommends Shorter & Safer Regimens

Ebola Outbreak Caused By Rare Bundibugyo Virus

Unlike many previous Ebola outbreaks caused by the Zaire ebolavirus, the ongoing epidemic is caused by the Bundibugyo virus, a rarer species of Ebola virus for which there is currently no approved vaccine or licensed treatment.

The World Health Organization (WHO) said the outbreak remains active with heightened community transmission, particularly in eastern DRC, where insecurity, mistrust, population displacement and limited healthcare access continue to hamper outbreak containment efforts.

WHO Warns

In its latest Disease Outbreak News update, WHO said, “The outbreak remains active, with sustained transmission.”

The UN health agency noted that inside conflict, population displacement, community mistrust and restricted access to affected areas continue to affect contact tracing, surveillance, and containment and treatment activities.

WHO has also stressed that although the global risk remains low, the regional risk is high because of frequent cross-border movement between the DRC and neighbouring countries.

A major challenge in controlling the epidemic is the absence of a licensed vaccine or targeted therapy against the Bundibugyo virus.

According to WHO, while the Ebola vaccine used against the Zaire strain has shown limited experimental cross-protection in animal studies, there is currently inadequate evidence to recommend its use against Bundibugyo virus disease.

Also read: Uganda Declared Ebola-Free As Congo Outbreak Grows To 3,262 Cases, 1,437 Deaths

First Volunteer Receives Experimental Bundibugyo Vaccine

Amid the worsening outbreak, researchers have reached an important milestone in Ebola vaccine development.

The first volunteer has received an experimental vaccine targeting the Bundibugyo strain of Ebola, marking the world's first Phase I clinical trial for this virus, according to the University of Oxford.

The vaccine, ChAdOx1 BDBV, developed in collaboration with Serum Institute of India (SII), is designed specifically to protect against the Bundibugyo strain of Ebola.

It uses the same viral vector platform that powered the Oxford-AstraZeneca COVID-19 vaccine.

The vaccine uses a genetically modified chimpanzee adenovirus (ChAdOx1)—a harmless virus that normally causes the common cold in chimpanzees—as a delivery vehicle.

"We welcome the start of the phase 1 clinical trial of an investigational vaccine against Ebola Bundibugyo virus disease—an important step to assess the safety and immune responses generated by the vaccine," said WHO Director-General Tedros Adhanom Ghebreyesus on X.

Health authorities, supported by WHO, Africa CDC and international partners, continue to strengthen surveillance, laboratory testing, infection prevention, community engagement and patient care.